Innovent Biologics, Inc. (HKG:1801)
85.50
+6.10 (7.68%)
At close: Mar 27, 2026
Innovent Biologics Employees
Innovent Biologics had 7,502 employees as of December 31, 2025. The number of employees increased by 1,843 or 32.57% compared to the previous year.
Employees
7,502
Change
1,843
Growth
32.57%
Revenue / Employee
1.93M HKD
Profits / Employee
120.68K HKD
Market Cap
148.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Jun 30, 2025 | 6,190 | - | - |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | 5,568 | 2,289 | 69.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 23,056 |
| WuXi Biologics | 12,552 |
| BeOne Medicines AG | 12,000 |
| 3SBio | 6,268 |
| Shanghai Henlius Biotech | 3,537 |
| Akeso | 3,529 |
| RemeGen | 3,070 |
| Shanghai Junshi Biosciences | 2,670 |
Innovent Biologics News
- 3 days ago - Innovent Announces 2025 Annual Results and Business Updates - PRNewsWire
- 5 days ago - Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD - Nasdaq
- 6 days ago - Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study - PRNewsWire
- 4 weeks ago - Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals - South China Morning Post
- 6 weeks ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer - PRNewsWire
- 6 weeks ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 6 weeks ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
- 7 weeks ago - Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology - PRNewsWire